Iryna Bilyk

Ms. Iryna Bilyk

orcid
Associate Professor, Candidate of Pharmaceutical Sciences, I...

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2022 in ScienceRise: Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
OSOleh Samborskyi
Oleh Samborskyi
НPНanna Panfilova
Нanna Panfilova
YBYuliia Baihush
Yuliia Baihush
LSLiusine Simonian
Liusine Simonian
IBIryna Bilyk
Iryna Bilyk
VCVitaly Chernukha
Vitaly Chernukha
The aim: to conduct an analysis of the state of functioning of pharmaceutical supply systems for the population in European countries and Ukraine based on a set of socio-economic indicators. Materials and methods. General theoretical (historical, formal, graphic, hypothetical-deductive) and applied (organizational-economic, mathematical-statistical) research methods were used. The object of research was data that was freely available. Results. It was established that the highest volume of the pharmaceutical market volume per inhabitant is typical for Italy (410.18 euros) and the lowest for Ukraine (53.58 euros). It has been proven that with an increase in GDP indicators, which are calculated based on purchasing power parity (PPP) per capita, the range of variation of this indicator by groups decreases, and the number of countries with a negative value of the foreign trade balance also decreases. Within groups of countries, there is a different level of dependence on the import of pharmaceutical products. In Ukraine (the first group), imports exceeded the export data of pharmaceutical products by 8.6 times. For other countries in this group (Latvia, Bulgaria, and Slovakia), imports exceeded exports by 1.3, 1.4, and 4.0 times, respectively. The highest values of the volume of foreign trade in pharmaceutical products were characteristic of the countries of the third and second groups. The undisputed leader is Germany (134,541.0 million euros), in second place is Italy (59,533.0 million euros), and in third place is France (58,568.0 million euros). The highest values of health care costs as a percentage of GDP (%) are typical for the countries of the third group and the lowest for the countries of the first group. For all countries, this indicator had a characteristic tendency to increase over time. Growth rates varied both across groups and within groups across countries. According to the indicator of the amount of reimbursement of the cost of drug consumption per person, there was a significant fluctuation of the data by country within the groups. The most extensive range of fluctuations was observed in the third group (284.83 euros). The highest reimbursement amounts are typical for Germany (483.53 euros) and the lowest for Bulgaria (54.25 euros). In most countries, there is a high level (50.0 % and higher) of state participation in the payment of medicine, except for Poland (36.0 %), Lithuania (34.0 %) and Latvia (37.0 %). The lowest values of money consumers spend to pay for medicines (from 13.0 % to 44.0 %) are characteristic of the countries of the third group. Conclusions. The established peculiarities of the functioning of the pharmaceutical supply systems of European countries should not diminish the value of the state's aspirations to harmonize the processes that take place to promote medicinal products to consumers

26 December 2025 in Farmatsevtychnyi zhurnal
Verified
Journal Article
Open access
PDF file
ГПГ. Л. Панфілова
Г. Л. Панфілова
ОСО. С. Самборський
О. С. Самборський
LTL. V. Tereshchenko
L. V. Tereshchenko
IBIryna Bilyk
Iryna Bilyk
ГЦГ. М. Ціхонь
Г. М. Ціхонь
HTH. М. Tsikhon
H. М. Tsikhon
Regulation of drug prices is considered an important tool in shaping the country's national pharmaceutical security. In early 2025, Ukraine introduced a number of regulatory innovations aimed at increasing the availability of drugs for the population. One of the directions of this process was the introduction of price referencing/declaration mechanisms and the introduction of the National Drug Price Catalog. The aim – to analyze the problems of implementing the National Price Catalog for Medicines into the system of pharmaceutical provision for the population in Ukraine. Data from official websites of state institutions operating in healthcare, professional mass media sources, as well as scientific publications on the specified topic were used. The research used theoretical research methods (historical, logical, critical approach of interpretative synthesis, etc.) The article analyzes the regulatory framework that is the basis for the effective implementation of the National Catalog of Drug Prices and the regulation of their availability in the healthcare system. A new definition of the «Regulatory group of drugs» is presented, which allows analyzing the impact of the relevant mechanisms on the availability of drugs. An analysis of the current version of the National Drug Price Catalog was conducted. It was proven that the introduction of referencing/declaration of drug prices should correspond to the levels of medical and pharmaceutical care provided to the population and not lead to excessive regulatory influence on the circulation of drugs. The main characteristics and problems of the implementation of the National Catalog of Drug Prices in Ukraine are identified and the directions for their solution are outlined. The introduction of mechanisms for summarizing and declaring prices on the pharmaceutical market in the absence of a preliminary study of the relevant risks, an assessment methodology and a system of indicators of the effectiveness of their implementation, and coordination of the opinions of various business entities may have unpredictable consequences for the sustainable development of the domestic healthcare system. Therefore, it is necessary to conduct a systematic analysis of the consequences of the introduction of the National Price Catalog into the domestic healthcare system and develop directions for further promotion of regulatory mechanisms in practical pharmacy.

19 December 2019 in Pharmacia
Verified
Journal Article
Open access
IBIryna Bilyk
Iryna Bilyk
IFIryna Fedyak
Iryna Fedyak
IIIryna Ivaniulyk Ivaniulyk
Iryna Ivaniulyk Ivaniulyk
Liubomyr Mykhailovych HavryshchukLiubomyr Mykhailovych Havryshchuk
Liubomyr Mykhailovych Havryshchuk
A comprehensive study for assessment the appointments rationality for children with meningococcal infectious (MI) in Ukraine in real clinical practice has been conducted. The doctor’s appointment sheets from 184 inpatients medical cards have been processed by the integral ABC / VEN / frequency analysis. In average, children were in the hospital (14±7) bed-days, they were granted 2908 appointments of 191 drugs by the INN. It has been established that medicine for MI etiotropic therapy took the third place in the appointments frequency. At the same time, the ABC / VEN-analysis results revealed a rational approach to pharmacotherapy.The total treatment cost was estimated at USD 25,173.59 (for one child – USD 136.81).Since currently in Ukraine inpatient children treatment is mainly provided by parents, further medical prescriptions improvement is needed in order to increase the efficiency and minimize the childrenMI therapy cost.

1 September 2019 in Wiadomości Lekarskie
Verified
Journal Article
Closed access
ODOryna Detsyk
Oryna Detsyk
IFIryna Fedyak
Iryna Fedyak
IBIryna Bilyk
Iryna Bilyk
Introduction: The level of childhood bacterial diseases incidence does not have a downward trend. The aim: Conduction of a sociological analysis of medical cards for children with pertussis, meningococcal infection (MI), scarlet fever, and evaluation of consumed pharmacotherapy according to real clinical practice in Ukraine. Materials and methods: 1215 medical cards of inpatients; methods: sociological - document analysis, retrospective frequency. Results: Among the cards of children with pertussis: 50.2% - female, 49.8%- male; by age children up to 1 year (49.3%) were prevailed. In 79.6% incidence - medium-hard form pertussis, 42.2% with complications. Among patients with MI by sex there were: 50.5 % - boys and 49.5% - girls; by age - children aged 1-4 (40.2%); the structure of generalized forms of MI: 40.2% - meningococcemia, 11.4% - meningitis, 48.4% - combination. Scarlet fever was more frequently: boys (56.4%), children aged 5-9 (44.7%), urban residents (79.7%); it was 93.4% of a medium-hard form. Most of medicines were prescribed to children with MI - 15.8 trade names per 1 person, it was prescribed 191 INN, most often - Sodium chloride (90.0%), Ascorbic acid (68.5%), Ceftriaxone (65.8%); patients with pertussis - 11.2, 196 INN (Chlorpromazine (69.1%), Dexamethasone (53.2%), Butamirate (51.8%)); scarlet fever - 9.3 medicines, 114 INN (local action Comb drug for throat diseases treatment (94.4%), Ceftriaxone (48.7%), Metamizole sodium (38.1%)). Conclusions: Frequency analysis data of consumed pharmacotherapy in real pediatric practice in Ukraine shows the need for its further optimization in accordance with the principles of evidence-based medicine, the results of research on the socio-demographic characteristics of patients, forms and complications of course of the basic disease.

22 September 2025 in Здобутки клінічної і експериментальної медицини
Verified
Journal Article
Open access
PDF file
LBLiliia Budniak
Liliia Budniak
IBIryna Bilyk
Iryna Bilyk
NMN. Ya. Muzyka
N. Ya. Muzyka
SCS. B. Chernetska
S. B. Chernetska
ІБІ. П. Білик
І. П. Білик
НMН. Я. Mузика
Н. Я. Mузика
SUMMARY. Vision is essential for human activity, yet over 2.2 billion people worldwide face visual impairments, many of which are preventable. Digital screen exposure further exacerbates eye health issues. While treatment options exist, their cost makes prevention increasingly relevant. The use of plant-based dietary supplements offers a viable preventive strategy. Analyzing their assortment, composition, and dosage forms is key to improving quality control and guiding the development of effective products for visual function support. The aim – to investigate the pharmaceutical assortment of dietary supplements for the normalization of visual function. Material and Methods. The objects of the study were the directory of Compendium online and online resources such as Tabletki.ua and Apteki.ua. The study employed marketing analysis, graphical representation, logical generalization, and mathematical-statistical methods. Results. As of April 2025, the pharmaceutical assortment comprised 104 dietary supplements for the normalization of visual function. The analysis of the assortment revealed a predominance of domestically produced dietary supplements, accounting for 55.77 %. The leaders among them were Beauty and Health, LLC (10.34 %) and Elit-Pharm, LLC (8.61 %). Imported dietary supplements originated from 16 countries, with the highest shares coming from Germany and the United States (19.57 % each). The majority of dietary supplements had a multi-component composition (86.54 %). The most common dosage forms were capsules and tablets. Conclusions. The domestic pharmaceutical market of dietary supplements for the normalization of visual function has been analyzed. The results indicate a predominance of domestically produced products, a multi-component structure of the assortment, and a variety of dosage forms, highlighting the high potential for further research and development based on plant-derived raw materials.